A Phase 2 interventional study of Eladocagene Exuparvovec in AADC Deficiency, sponsored by PTC Therapeutics. Active, not recruiting at 6 sites in 3 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by PTC Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will have a trial phase, extension phase, and a long-term extension phase. The primary objectives of the trial phase are to assess the pharmacodynamics (PD) of eladocagene exuparvovec treatment by evaluation of homovanillic acid (HVA) levels and to assess the safety of the SmartFlow® magnetic resonance (MR) Compatible Ventricular Cannula for administering eladocagene exuparvovec to pediatric participants with aromatic L-amino acid decarboxylase (AADC) deficiency. The extension phase is designed to capture additional clinical information for eladocagene exuparvovec through study evaluations, changes in motor development, AADC-specific symptoms, and other PD measures. The long-term extension phase is designed to capture long-term safety and efficacy data from participants treated with eladocagene exuparvovec.
PTC Therapeutics is the lead sponsor of 65 studies on the registry; 3 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 14 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive eladocagene exuparvovec intraoperatively at 1.8×10\^11 vector genomes (vg) via SmartFlow® MR Compatible Ventricular Cannula in a single operative session. Participants will receive standard of care for their AADC deficiency during the study.
Genetic: Eladocagene Exuparvovec
Four 0.08 milliliters (mL) infusions at a dose of 0.45×10\^11 vg and a volume of 80 microliters (μl) per site to 4 sites (2 per putamen), for the total dose of 1.8×10\^11 vg and a total volume of 320 μl per participant.
Also known as: KEBILIDI™
Change From Baseline in HVA Metabolite Level at the End of the Trial Phase
HVA is a main metabolite of dopamine and HVA CSF levels are recognized as a proxy for dopamine levels in the brain.
Time frame: Baseline (Day 1), Week 8
Number of Participants With Adverse Events (AEs) Associated With the Surgical Administration of Eladocagene Exuparvovec Using the SmartFlow® MR-Compatible Ventricular Cannula
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered related to the drug. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease in a study participant who was administered gene therapy in this study. Number of participants with AEs related to the SmartFlow MR-compatible ventricular cannula used to administer eladocagene exuparvovec to pediatric participants at the end of Trial Phase (8 weeks after administration) are reported. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module."
Time frame: Baseline (Day 1) up to Week 8
Change From Baseline in Neurotransmitter Cerebrospinal Fluid (CSF) Metabolite HVA at Week 48
Time frame: Baseline (Day 1), Week 48
Change From Baseline in Positron Emission Tomography (PET) Imaging of Putaminal-Specific L-6-[18F] Fluoro-3,4-Dihydroxyphenylalnine (18F-DOPA) PET Uptake at the End of the Trial Phase (Week 8) and the Extension Phase (Week 48)
Time frame: Baseline (Day 1), Week 8, Week 48
Change From Baseline in Neurotransmitter CSF Metabolites 5-hydroxyindoleacetic Acid (5-HIAA), and 3-O-methyldopa (3-OMD) at Weeks 8 and 48
Time frame: Baseline (Day 1), Weeks 8 and 48
Number of Participants Who Attain Motor Milestones
Time frame: Baseline (Day 1) up to Week 260
Change in Peabody Developmental Motor Scale, Second Edition (PDMS-2)
Time frame: Baseline (Day 1), Week 260
Change in Bayley Scale of Infant Development, Third Edition (Bayley-III)
Time frame: Baseline (Day 1), Week 260
Change in EuroQol-5 Dimensions Youth Version (EQ-5D-Y)
Time frame: Baseline (Day 1), Week 260
Change in Body Weight
Time frame: Baseline (Day 1), Week 260
Number of Participants With AADC-Specific Symptoms
Time frame: Baseline (Day 1) up to Week 260
"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) "
Time frame: Baseline (Day 1) up to Week 260
| Milestone | Eladocagene Exuparvovec |
|---|---|
| Started | 13 |
| Received at least 1 dose of study drug | 13 |
| Completed | 13 |
| Not completed | 0 |
| Milestone | Eladocagene Exuparvovec |
|---|---|
| Started | 13 |
| Completed | 9 |
| Not completed | 4 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Ongoing in the study | 3 |
| Milestone | Eladocagene Exuparvovec |
|---|---|
| Started | 7 |
| Completed | 0 |
| Not completed | 7 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Ongoing in the study | 6 |
HVA is a main metabolite of dopamine and HVA CSF levels are recognized as a proxy for dopamine levels in the brain.
| nmol/L | Eladocagene Exuparvovec |
|---|---|
| Change From Baseline in HVA Metabolite Level at the End of the Trial Phase | 29.53 ± 12.93 |
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered related to the drug. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease in a study participant who was administered gene therapy in this study. Number of participants with AEs related to the SmartFlow MR-compatible ventricular cannula used to administer eladocagene exuparvovec to pediatric participants at the end of Trial Phase (8 weeks after administration) are reported. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module."
| Participants | Eladocagene Exuparvovec |
|---|---|
| Number of Participants With Adverse Events (AEs) Associated With the Surgical Administration of Eladocagene Exuparvovec Using the SmartFlow® MR-Compatible Ventricular Cannula | 0 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over Baseline (Day 1) up to the interim data cut-off date (up to 897 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eladocagene Exuparvovec | 0/13 (0%) | 9/13 (69.2%) | 13/13 (100%) |
| Event | Eladocagene Exuparvovec |
|---|---|
| PneumoniaInfections and infestations | 3/13 |
| BradycardiaCardiac disorders | 1/13 |
| VomitingGastrointestinal disorders | 1/13 |
| PyrexiaGeneral disorders | 1/13 |
| Bacterial infectionInfections and infestations | 1/13 |
| COVID-19Infections and infestations | 1/13 |
| Metapneumovirus pneumoniaInfections and infestations | 1/13 |
| Pneumonia viralInfections and infestations | 1/13 |
| Urinary tract infectionInfections and infestations | 1/13 |
| DyskinesiaNervous system disorders | 1/13 |
| Event | Eladocagene Exuparvovec |
|---|---|
| PyrexiaGeneral disorders | 10/13 |
| DyskinesiaNervous system disorders | 10/13 |
| DiarrhoeaGastrointestinal disorders | 8/13 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/13 |
| Dermatitis diaperSkin and subcutaneous tissue disorders | 5/13 |
| AnaemiaBlood and lymphatic system disorders | 4/13 |
| VomitingGastrointestinal disorders | 4/13 |
| NasopharyngitisInfections and infestations | 4/13 |
| HypotensionVascular disorders | 4/13 |
| Salivary hypersecretionGastrointestinal disorders | 3/13 |
The safety population included all participants enrolled in the study who have received any amount of study drug.
| Age, Continuous(months) | Eladocagene Exuparvovec |
|---|---|
| Mean | 45.2 ± 29.48 |
| Sex: Female, Male(Participants) | Eladocagene Exuparvovec |
|---|---|
| Female | 7 |
| Male | 6 |
| Ethnicity (NIH/OMB)(Participants) | Eladocagene Exuparvovec |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 10 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Eladocagene Exuparvovec |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 10 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 2 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Homovanillic Acid (HVA) Metabolite Level(nanomoles (nmol)/liter (L)) | Eladocagene Exuparvovec |
|---|---|
| Mean | 22.54 ± 32.34 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2021 to primary completion in May 2023, 24 months.
Results were first posted in Jan 2025, 1 year 7 months after primary completion. A results delay was requested in May 2024.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aromatic amino acid decarboxylase deficiency